Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 23, 2017

DrugPatentWatch Database Preview

GLEEVEC Drug Profile

« Back to Dashboard

What is the patent landscape for Gleevec, and when can generics launch?

Gleevec is a drug marketed by Novartis and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in GLEEVEC is imatinib mesylate. There are thirty-one drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.

Summary for Tradename: GLEEVEC

Patents:4
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list101
Clinical Trials: see list80
Patent Applications: see list9,646
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GLEEVEC at DailyMed

Pharmacology for Tradename: GLEEVEC

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335-001May 10, 2001DISCNYesNo6,894,051*PED► SubscribeY► Subscribe
Novartis
GLEEVEC
imatinib mesylate
TABLET;ORAL021588-001Apr 18, 2003ABRXYesNo6,894,051*PED► SubscribeY► Subscribe
Novartis
GLEEVEC
imatinib mesylate
CAPSULE;ORAL021335-002May 10, 2001DISCNYesNo6,894,051*PED► SubscribeY► Subscribe
Novartis
GLEEVEC
imatinib mesylate
TABLET;ORAL021588-002Apr 18, 2003ABRXYesYes6,894,051*PED► SubscribeY► Subscribe
Novartis
GLEEVEC
imatinib mesylate
TABLET;ORAL021588-001Apr 18, 2003ABRXYesNo6,958,335*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Formulary management
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot